Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated RadiotherapyHale Başak Çağlar, Aaron M. Allen, Roy B. Tishler et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 230
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Aaron M. Allen et al.|Journal of Thoracic Oncology|2018Cited by 220
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancerRobert I. Haddad, Roy B. Tishler, Stephen T. Sonis et al.|Cancer|2009Cited by 98
Efficacy and toxicity of reirradiation using intensity‐modulated radiotherapy for recurrent or second primary head and neck cancerDavid J. Sher, Roy B. Tishler, Robert I. Haddad et al.|Cancer|2010Cited by 79
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Elias Bshara et al.|Lung Cancer|2018Cited by 75